Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants (FiO2-C)
Effects of Closed-loop Automatic Control of the Inspiratory Fraction of Oxygen (FiO2-C) on Outcome of Extremely Preterm Infants - a Randomized Controlled Parallel Group Multicenter Trial for Safety and Efficacy
Sponsor: University Hospital Tuebingen
This PHASE3 trial investigates Infant,Premature and is currently ongoing. University Hospital Tuebingen leads this study, which shows 10 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting · Phase: NA → PHASE3
-
Aug 2023 — Jan 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Oct 2021 — Aug 2023 [monthly]
Recruiting NA
-
Jan 2021 — Oct 2021 [monthly]
Recruiting NA
-
Jan 2019 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting NA
-
Jul 2017 — Jun 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amberg, Germany , Augsburg, Germany , Bad Kreuznach, Germany , Bremen, Germany , Dresden, Germany , Düsseldorf, Germany , Erfurt, Germany , Esslingen am Neckar, Germany , Freiburg im Breisgau, Germany , Hanover, Germany and 21 more locations